Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.68 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.68 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | CASP7 | P55210 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13500597 | 0.84 | HSD17B10 (0.66) | NPC1MTORIRAK1IRAK4HSD17B10 | |
| SCHEMBL29363239 | 0.81 | IRAK4 (1.00) | MTORIRAK1IRAK4HSD17B10CASP1 | |
| SCHEMBL3600534 | 0.81 | IRAK4 (1.00) | MTORIRAK1IRAK4HSD17B10CASP1 | |
| SCHEMBL19249754 | 0.80 | IRAK4 (0.70) | NPC1MTORIRAK1IRAK4HSD17B10 | |
| SCHEMBL6499836 | 0.77 | KDM4E (0.74) | MTORIRAK1IRAK4HSD17B10CASP1 | |
| SCHEMBL6530642 | 0.77 | KDM4E (1.00) | MTORIRAK1IRAK4HSD17B10CASP1 | |
| SCHEMBL3598210 | 0.76 | OPRK1 (0.85) | MTORIRAK1IRAK4HSD17B10CASP1 | |
| SCHEMBL16261073 | 0.74 | MTOR (0.74) | MTORIRAK1IRAK4HSD17B10CASP1 | |
| SCHEMBL3600001 | 0.74 | MTOR (0.70) | MTORIRAK1IRAK4HSD17B10CASP1 | |
| SCHEMBL21563983 | 0.74 | TSHR (0.70) | HSD17B10KDM4EKMT2ATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | MACHAKEWSKI TIMOTHY D | 2010-01-07 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-7132438-B2 | Benzimidazole derivatives | AMGEN INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1434579-A1 | IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | Tularik Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030144286-A1 | Benzimidazole derivatives | TULARIK, INC | 2003-07-31 | — | — | US | disclosed |
| WO-2003030902-A1 | IMIDAZOLE DERIVATES AS ANTI-INFLAMMATORY AGENTS | TULARIK INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | IDO2, IRF2BP2, IRF3 | NPC1 4428/4885MTOR 96/4885IRAK1 121/4885 |
| US-20030144286-A1 | Benzimidazole derivatives | NFATC1, STAT1, IRF3 | NPC1 3547/4885MTOR 160/4885IRAK1 87/4885 |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | NFATC1, STAT1, IRF3 | NPC1 3547/4885MTOR 160/4885IRAK1 87/4885 |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | TYMP, TPMT, TYMS | NPC1 2942/4885MTOR 2271/4885IRAK1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.